Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Liquidia CorpLQDA · Entity 1860 | SVP, Human Resources | January 19, 2021 | January 20, 2021 |
| Liquidia Technologies IncLQDA · Entity 145051 | SVP, Human Resources | March 18, 2020 | March 20, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Liquidia Corp
Report date January 19, 2021 · Filed January 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2031-01-19 | Direct | 55,300 |
Reported balance
After 2021-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-19 · Grant · Acquired 55,300 · Balance 55,300 F1: The option vests in equal monthly installments over a four-year period, becoming fully vested on January 19, 2025. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 27,650 |
Reported balance
After 2021-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-19 · Grant · Acquired 27,650 · Balance 27,650 F2: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over a four-year period, becoming fully vested on January 19, 2025.
F2: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer.
Liquidia Technologies Inc
Report date March 18, 2020 · Filed March 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,991 |
Reported balance
After 2020-03-18 transaction · row 1
1 source rowRow 1 · 2020-03-18 · Grant · Acquired 7,500 · Balance 16,991 F1: The restricted stock units (RSUs) vest and settle into common stock over a four-year period with 25% of the RSUs vesting and settling into common stock on the one year anniversary of the grant date and the remaining 75% of the RSUs vesting and settling into common stock in equal quarterly installments over the next three years, becoming fully vested on March 18, 2024. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.31 · Expires 2030-03-18 | Direct | 30,000 |
Reported balance
After 2020-03-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-18 · Grant · Acquired 30,000 · Balance 30,000 F2: The option vests in equal monthly installments over a four-year period, becoming fully vested on March 18, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (RSUs) vest and settle into common stock over a four-year period with 25% of the RSUs vesting and settling into common stock on the one year anniversary of the grant date and the remaining 75% of the RSUs vesting and settling into common stock in equal quarterly installments over the next three years, becoming fully vested on March 18, 2024.
F2: The option vests in equal monthly installments over a four-year period, becoming fully vested on March 18, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2021 Filed Jan 20, 2021 20:29 UTC | Liquidia Corp LQDA · Entity 1860 | GrantPerformance Stock Units · Derivative | 27,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-005987 · tm213622-4_4seq1.xml · derivative · entry 2 Krawchick Florina · CIK 0001783634 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,650 Underlying: Common Stock · 27,650 shares Expires not disclosed F2 · derivative.exercise_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.expiration_date: The performance stock units (PSUs) vest in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 20:29 UTC | Liquidia Corp LQDA · Entity 1860 | GrantEmployee Stock Option (right to buy) · Derivative | 55,300 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001104659-21-005987 · tm213622-4_4seq1.xml · derivative · entry 1 Krawchick Florina · CIK 0001783634 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,300 Underlying: Common Stock · 55,300 shares Expires 2031-01-19 F1 · derivative.exercise_date: The option vests in equal monthly installments over a four-year period, becoming fully vested on January 19, 2025. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 19:09 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0001104659-20-036986 · a4.xml · derivative · entry 2 Krawchick Florina · CIK 0001783634 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-03-18 F2 · derivative.exercise_date: The option vests in equal monthly installments over a four-year period, becoming fully vested on March 18, 2024. Read SEC document |
| March 18, 2020 Filed Mar 20, 2020 19:09 UTC | Liquidia Technologies Inc LQDA · Entity 145051 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-036986 · a4.xml · nonDerivative · entry 1 Krawchick Florina · CIK 0001783634 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,991 F1 · shares: The restricted stock units (RSUs) vest and settle into common stock over a four-year period with 25% of the RSUs vesting and settling into common stock on the one year anniversary of the grant date and the remaining 75% of the RSUs vesting and settling into common stock in equal quarterly installments over the next three years, becoming fully vested on March 18, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.